{"created":"2023-06-20T14:26:48.945310+00:00","id":2503,"links":{},"metadata":{"_buckets":{"deposit":"11565ac6-87f1-45e2-8efe-15e63422c0ea"},"_deposit":{"created_by":14,"id":"2503","owners":[14],"pid":{"revision_id":0,"type":"depid","value":"2503"},"status":"published"},"_oai":{"id":"oai:dmu.repo.nii.ac.jp:00002503","sets":["81:191"]},"author_link":["371","10892","10895","6909","6407","10894","10893","9"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-03-25","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"42","bibliographicPageStart":"33","bibliographicVolumeNumber":"48","bibliographic_titles":[{"bibliographic_title":"Dokkyo Journal of Medical Sciences"}]}]},"item_10001_description_35":{"attribute_name":"要旨(英)","attribute_value_mlt":[{"subitem_description":"Hyperkalemia is known as a major adverse effect of nafamostat, a serine protease inhibitor, and its mechanism is thought as inhibition of an amiloride-sensitive Na＋ channel. Kallikrein is a serine protease and can activate the amiloride-sensitive Na＋ channel. The study examined whether urine potassium excretion and kallikrein activity decrease in a nafamostat-induced hyperkalemia model. First, rats were administered nafamostat（1.2 mg/kg/h）or 5％ glucose by a continuous intravenous infusion（c.i.）under general anesthesia, and urine and blood samples were collected every 15 minutes from 30 minutes before until 90 minutes after drug administration. Next, nafamostat（0.13, 0.4, 1.2 mg/kg/h c.i.）or 5％ glucose was co-administered by a low-dose amiloride（3.33 µg/kg i.v. followed by 12 µg/kg/h c.i.）in the same time course. Changes in Δ serum potassium concentrations, a difference from the baseline, and those in urine potassium excretion and kallikrein activity, and their means of the last three points were evaluated. Statistical analyses were conducted by a repeated measure ANOVA（α＝0.05, one-tail test）. In results, increasing and decreasing trends were observed regarding with the changes in Δ potassium and potassium excretion, and their corresponding means of the last three points, respectively, in the nafamostat group compared with control group. In the next experiment, changes in the Δ serum potassium concentrations and those in urine potassium excretion, and their corresponding means of the last three points significantly increased and decreased, respectively, in the nafamostat group compared with the control group. A significant decrease in urine kallikrein activity was shown by the maximum dose of nafamostat regarding with the means of the last three points compared to the control. In conclusions, nafamostat induced renal hyperkalemia in vivo via inhibition of the amiloride-sensitive Na＋ channel, which was associated with inhibition of urine kallikrein activity.","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"獨協医学会"}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA00629581","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03855023","subitem_source_identifier_type":"ISSN"}]},"item_10001_text_25":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Department of Anesthesiology, Dokkyo Medical University School of Medicine, Tochigi 321-0293, Japan"},{"subitem_text_language":"en","subitem_text_value":"Research Center for Laboratory Animals, Dokkyo Medical University School of Medicine"},{"subitem_text_language":"en","subitem_text_value":"Research Center for Laboratory Animals, Dokkyo Medical University School of Medicine"},{"subitem_text_language":"en","subitem_text_value":"Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine"},{"subitem_text_language":"en","subitem_text_value":"Department of Anesthesiology, Dokkyo Medical University School of Medicine, Tochigi 321-0293, Japan"},{"subitem_text_language":"en","subitem_text_value":"Department of Anesthesiology, Dokkyo Medical University School of Medicine, Tochigi 321-0293, Japan"},{"subitem_text_language":"en","subitem_text_value":"Department of Anesthesiology, Dokkyo Medical University School of Medicine, Tochigi 321-0293, Japan"},{"subitem_text_language":"en","subitem_text_value":"Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine"}]},"item_10001_text_33":{"attribute_name":"記事種別","attribute_value_mlt":[{"subitem_text_value":"Original"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yamada, Teppei","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kaneko, Hiromichi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Inose, Chihiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tanaka-Nakadate, Sawako","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hanawa, Hiroki","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hamaguchi, Shinsuke","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yamaguchi, Shigeki","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Fujita, Tomoe","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-05-20"}],"displaytype":"detail","filename":"DJMS-48-1-5.pdf","filesize":[{"value":"517.3 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"DJMS-48-1-Yamada-本文","url":"https://dmu.repo.nii.ac.jp/record/2503/files/DJMS-48-1-5.pdf"},"version_id":"cf257bf0-a9fe-4d04-bdc1-04f2f1b271be"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Tissue kallikrein","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Nafamostat","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Amiloride","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Renal hyperkalemia","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Rat","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Effect of In-vivo Administration of Nafamostat on the Onset of Renal Hyperkalemia and Association of Urine Kallikrein in Rats","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Effect of In-vivo Administration of Nafamostat on the Onset of Renal Hyperkalemia and Association of Urine Kallikrein in Rats"}]},"item_type_id":"10001","owner":"14","path":["191"],"publish_date":"2021-05-21","publish_status":"0","recid":"2503","relation_version_is_last":true,"title":["Effect of In-vivo Administration of Nafamostat on the Onset of Renal Hyperkalemia and Association of Urine Kallikrein in Rats"],"weko_creator_id":"14","weko_shared_id":-1},"updated":"2023-06-20T14:50:37.542076+00:00"}